Adial Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Adial Pharmaceuticals, Inc. (ADIL) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$176.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$95.18K.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$80.82K.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$107.88K.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $244.30K, a 10.44% increase year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$8.57K.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$63.36K, a 385.96% decline from fiscal 2023.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $22.16K.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$40.06K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$95.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$176.00K 10-Q · filed 2026-08-14 | -$283.88K derived: sum of 3 quarters · filed 2026-08-14 | -$39.57K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$80.82K 10-Q · filed 2026-05-08 | -$188.69K derived: sum of 2 quarters · filed 2026-05-08 | $55.61K derived: sum of 3 quarters · filed 2026-05-08 | -$44.55K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | -$107.88K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $136.43K derived: sum of 2 quarters · filed 2026-03-05 | $36.27K derived: sum of 3 quarters · filed 2026-08-14 | -$8.57K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $244.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $144.15K derived: sum of 2 quarters · filed 2026-08-14 | $99.30K 10-Q · filed 2025-11-13 | -$2.26K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | -$100.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$145.00K 10-Q · filed 2026-08-14 | -$144.59K 10-Q · filed 2025-08-13 | -$246.57K derived: sum of 3 quarters · filed 2026-08-14 | -$25.36K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | -$44.84K 10-Q · filed 2026-05-08 | -$146.41K derived: sum of 2 quarters · filed 2026-05-08 | $74.80K derived: sum of 3 quarters · filed 2026-05-08 | -$11.96K derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | -$101.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $119.64K derived: sum of 2 quarters · filed 2026-03-05 | $32.88K derived: sum of 3 quarters · filed 2026-03-05 | -$63.36K 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $221.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $134.45K derived: sum of 2 quarters · filed 2025-11-13 | $38.21K 10-Q · filed 2025-11-13 | -$59.80K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$86.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$183.00K 10-Q · filed 2025-08-13 | -$281.01K derived: sum of 3 quarters · filed 2025-08-13 | $97.23K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | -$96.24K 10-Q · filed 2025-05-14 | -$194.25K derived: sum of 2 quarters · filed 2025-05-14 | $183.99K derived: sum of 3 quarters · filed 2025-05-14 | $52.00K derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$98.01K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $280.23K derived: sum of 2 quarters · filed 2024-11-13 | $148.24K derived: sum of 3 quarters · filed 2024-11-13 | $22.16K 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $378.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $246.25K derived: sum of 2 quarters · filed 2024-11-13 | $120.17K 10-Q · filed 2024-11-13 | -$34.63K derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | -$131.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$258.07K 10-Q · filed 2024-08-13 | -$412.87K derived: sum of 3 quarters · filed 2024-08-13 | -$102.69K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | -$126.08K 10-Q · filed 2023-05-12 | -$280.88K derived: sum of 2 quarters · filed 2024-04-01 | $29.30K derived: sum of 3 quarters · filed 2024-04-01 | -$42.54K derived: sum of 4 quarters · filed 2024-04-01 | |||
| 2022-12-31 | -$154.80K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $155.39K derived: sum of 2 quarters · filed 2024-04-01 | $83.54K derived: sum of 3 quarters · filed 2024-04-01 | -$40.06K 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $310.19K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | $238.34K derived: sum of 2 quarters · filed 2023-11-14 | $114.74K 10-Q · filed 2023-11-14 | $114.60K 10-Q · filed 2022-11-14 | -$65.55K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$71.84K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-10-30 | -$195.45K 10-Q/A · filed 2023-10-30 | -$375.73K derived: sum of 3 quarters · filed 2023-10-30 | $46.98K derived: sum of 4 quarters · filed 2023-10-30 | |||
| 2022-03-31 | -$123.60K 10-Q · filed 2023-05-12 | -$303.89K derived: sum of 2 quarters · filed 2023-05-12 | $118.82K derived: sum of 3 quarters · filed 2023-05-12 | -$31.61K derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | -$180.28K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $242.43K derived: sum of 2 quarters · filed 2023-03-30 | $91.99K derived: sum of 3 quarters · filed 2023-03-30 | -$112.19K 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $422.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $272.27K derived: sum of 2 quarters · filed 2022-11-14 | $68.09K 10-Q · filed 2022-11-14 | -$23.05K derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | -$150.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$354.62K 10-Q · filed 2022-08-15 | -$445.75K derived: sum of 3 quarters · filed 2022-08-15 | -$29.69K derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | -$204.18K 10-Q · filed 2022-05-16 | -$295.32K derived: sum of 2 quarters · filed 2022-05-16 | $120.75K derived: sum of 3 quarters · filed 2022-05-16 | $57.13K derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$91.14K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $324.93K derived: sum of 2 quarters · filed 2022-03-28 | $261.31K derived: sum of 3 quarters · filed 2022-03-28 | $142.19K 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $416.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $352.45K derived: sum of 2 quarters · filed 2021-11-15 | $233.33K 10-Q · filed 2021-11-15 | $81.95K derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | -$63.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$182.74K 10-Q · filed 2021-08-12 | -$334.12K derived: sum of 3 quarters · filed 2021-08-12 | $21.56K derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | -$119.12K 10-Q · filed 2021-05-17 | -$270.50K derived: sum of 2 quarters · filed 2021-05-17 | $85.17K derived: sum of 3 quarters · filed 2021-05-17 | -$39.04K derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | -$151.38K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $204.29K derived: sum of 2 quarters · filed 2021-03-22 | $80.08K derived: sum of 3 quarters · filed 2021-03-22 | $41.95K 10-K · filed 2021-03-22 | |||
| 2019-09-30 | $355.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $231.46K derived: sum of 2 quarters · filed 2020-11-13 | $193.33K 10-Q · filed 2020-11-13 | $82.28K derived: sum of 4 quarters · filed 2020-11-13 | |||
| 2019-06-30 | -$124.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$162.34K 10-Q · filed 2020-08-13 | -$273.39K derived: sum of 3 quarters · filed 2020-08-13 | $125.16K derived: sum of 4 quarters · filed 2020-08-13 | |||
| 2019-03-31 | -$38.13K 10-Q · filed 2020-05-14 | -$149.17K derived: sum of 2 quarters · filed 2020-05-14 | $249.38K derived: sum of 3 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | -$111.05K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $287.50K derived: sum of 2 quarters · filed 2020-03-20 | $308.55K 10-K · filed 2020-03-20 | $814.51K 10-K · filed 2019-02-19 | |||
| 2018-09-30 | $398.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $419.59K 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | $21.04K 10-Q · filed 2019-08-13 | ||||||
| 2017-12-31 | -$22.37K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | -$22.37K derived: sum of 2 quarters · filed 2019-02-19 | -$9.67K 10-K · filed 2019-02-19 | ||||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $12.70K 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | $12.70K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |